Ligand id: 7385

Name: catumaxomab

Compound class Antibody
Approved drug? Yes (EMA (2009))
Withdrawn drug? Yes
International Nonproprietary Names
INN number INN
8406 catumaxomab
L01XC09 | Removab®
Catumaxomab belongs to a novel group of engineered monoclonal antibodies termed trifunctional antibodies [4-5], which typically bind two specific epitopes. Catumaxomab binds the target cell specific antigen CD3E and the T cell specific antigen EpCAM (binding associated with the antibody variable Fv domains). The third type of antigen bound by catumaxomab are the Fcγ receptors on cells such as monocytes/macrophages, natural killer cells and dendritic cells (binding via intact antibody constant domain). Binding across all 3 epitopes selectively targets the immune destruction of target cells e.g. specific cancer cells. In this case the antibody is also hybrid, in that it contains peptide chains of different species origin; one heavy chain and one light chain from mouse and the same from rat [5].
Database Links
Specialist databases
IMGT/mAb-DB 218
Other databases
ChEMBL Ligand CHEMBL2108581
GtoPdb PubChem SID 178103957
PubChem SID 178103957
Search PubMed clinical trials catumaxomab
Search PubMed titles catumaxomab
Search PubMed titles/abstracts catumaxomab
Wikipedia Catumaxomab